Defining immune-active mechanisms of PDL1V in translational ADC development
Year: 2026
Type: article
Abstract: “Our observation of synergistic antitumor activity at multiple nonclinical doses supports that PDL1V allows the functional activation and trafficking of PD-L1-positive cytotoxic immune cells within a wide therapeutic window.”Lauren Coyle (Launch Commissioning Editor, Bioconjugate Insights) speaks with Megan Atkins (Senior Scientist, Translational Pharmacology, Pfizer) about advancing PDL1V from non-clinical characterization to pivotal trials, and how deeper immune profiling is reshaping the future of immune-active ADCs.
Source: Bioconjugation Insights
Author: Megan Atkins
Institution: Pfizer (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7124927080
FWCI:
Cites:
Cited by:
Related to: